15:40 EDT Pacira trading resumes
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
- Pacira price target lowered to $37 from $41 at Raymond James
- Pacira price target lowered to $37 from $42 at RBC Capital
- Pacira backs FY24 revenue view $680M-$705M, consensus $694.66M
- Pacira reports Q2 EPS 89c, consensus 70c